IBSA, a global leader in pharmaceutical innovation, will once again participate in CPhI Japan 2025, reinforcing its commitment to the Asia-Pacific region. As one of the most significant international events in the pharmaceutical industry, CPhI Japan offers an excellent opportunity for IBSA to showcase its innovative solutions and engage with key stakeholders, including potential partners, distributors, and clients.
“Japan and the broader Asia-Pacific region represent significant growth opportunities for IBSA,” says Andrea Taborelli, Senior Business Development and Licensing Manager. “CPhI Japan is the perfect stage for us to highlight our advanced pharmaceutical solutions, strengthen relationships within this dynamic market, and demonstrate how our cutting-edge technologies meet global market needs.”
Key Products on Display
IBSA will showcase some of its flagship products, particularly in the osteoarticular field, where it has established itself as a leader in innovation. Sinovial® HL and Sinogel® are pre-filled syringes designed for intra-articular injections that use hybrid hyaluronic acid, ensuring effective pain relief and improved mobility for patients with degenerative and post-traumatic conditions. These solutions are developed with NAHYCO® HYBRID TECHNOLOGY, a proprietary innovation that enables high hyaluronic acid concentration while ensuring ease of use and safety during administration. Also within the osteoarticular area, IBSA will present Ditralia®, its new vitamin D3 formulation, available in orodispersible film and softgel capsules, designed to support bone metabolism care.
Among its uro-gynaecology products, IBSA will highlight:
- Ialuril® Prefill, a pre-filled syringe designed to restore the glycosaminoglycan layers of the urothelial vesical tissue;
- Hyaluxelle®, a specialized product, based on high and low molecular weight hyaluronic acid, for women’s intimate health, addressing vaginal atrophy, dryness, and related symptoms.
Finally, representing IBSA’s excellence in Reproductive Medicine, two key products will be featured:
- Meriofert, indicated for the induction of ovulation in amenorrheic or anovulatory women who have not responded to treatment with clomiphene citrate;
- Prolutex®, the first water-based progesterone solution for luteal phase support, a valuable ally for Assisted Reproductive Technology patients.
A Commitment to Global Expansion
Founded in 1945 and headquartered in Lugano, Switzerland, IBSA operates in over 90 countries across five continents, with 20 subsidiaries in Europe, China, and the USA. In the past decade, it has expanded significantly, strengthening its global presence. IBSA continues to seek partners and international distributors for licensing agreements and has identified the Asia-Pacific region as a key area for future growth.
Meet IBSA at CPhI Japan 2025
IBSA invites partners, distributors, and industry professionals to explore its latest innovations at CPhI Japan 2025. Visit our stand at the Italia Pavilion to discover advanced pharmaceutical solutions designed for the global market.
